HYPR icon

Hyperfine

1.24 USD
-0.01
0.80%
Updated Aug 26, 9:37 AM EDT
1 day
-0.80%
5 days
-1.59%
1 month
12.73%
3 months
87.88%
6 months
25.25%
Year to date
26.53%
1 year
21.57%
5 years
-86.51%
10 years
-86.51%
 

About: Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.

Employees: 111

0
Funds holding %
of 7,429 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

8% more capital invested

Capital invested by funds: $7.07M [Q1] → $7.61M (+$542K) [Q2]

3% more funds holding

Funds holding: 38 [Q1] → 39 (+1) [Q2]

1.13% more ownership

Funds ownership: 15.7% [Q1] → 16.83% (+1.13%) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$0.85
31%
downside
Avg. target
$1.43
15%
upside
High target
$2
61%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
Wells Fargo
Larry Biegelsen
31%downside
$0.85
Equal-Weight
Maintained
15 Aug 2025
Lake Street
Frank Takkinen
61%upside
$2
Buy
Maintained
14 Aug 2025

Financial journalist opinion

Based on 9 articles about HYPR published over the past 30 days

Neutral
Business Wire
1 day ago
Hyperfine, Inc. to Participate in Upcoming Investor Conferences
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced their schedule for upcoming investor conferences. Hyperfine will discuss with investors recently announced milestones and growth catalysts, including its two major new technology clearances, commercial launch and market feedback.
Hyperfine, Inc. to Participate in Upcoming Investor Conferences
Positive
Zacks Investment Research
1 week ago
Hyperfine (HYPR) Upgraded to Buy: Here's Why
Hyperfine (HYPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Hyperfine (HYPR) Upgraded to Buy: Here's Why
Neutral
Seeking Alpha
1 week ago
Hyperfine, Inc. (HYPR) Q2 2025 Earnings Call Transcript
Hyperfine, Inc. (NASDAQ:HYPR ) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Brett Hale - Chief Administrative Officer, CFO, Chief Compliance Officer, Treasurer & Corporate Secretary Maria Sainz - CEO, President & Director Conference Call Participants Brandon Carney - B. Riley Securities, Inc., Research Division Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division Gursimran Kaur - Wells Fargo Securities, LLC, Research Division Webb Campbell - Unidentified Company Operator Good afternoon, and welcome to Hyperfine's Second Quarter 2025 Earnings Conference Call.
Hyperfine, Inc. (HYPR) Q2 2025 Earnings Call Transcript
Neutral
Zacks Investment Research
1 week ago
Hyperfine, Inc. (HYPR) Reports Q2 Loss, Lags Revenue Estimates
Hyperfine, Inc. (HYPR) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.14 per share a year ago.
Hyperfine, Inc. (HYPR) Reports Q2 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
1 week ago
Hyperfine, Inc. Reports Second Quarter 2025 Financial Results
GUILFORD, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2025 financial results and provided a business update.
Hyperfine, Inc. Reports Second Quarter 2025 Financial Results
Neutral
Business Wire
3 weeks ago
Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop® System
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine hits 100-patient milestone in portable MRI study, accelerating access to brain imaging in neurology clinics with next-gen Swoop® system.
Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop® System
Neutral
Business Wire
3 weeks ago
Hyperfine Announces First Patients Enrolled in PRIME Study Aimed at Accelerating Adoption of AI-Powered Portable MRI in Emergency Departments
GUILFORD, Conn.--(BUSINESS WIRE)--First patients enrolled in PRIME study at Yale School of Medicine, aiming to evaluate the potential of AI-powered portable MRI tech in the ED setting.
Hyperfine Announces First Patients Enrolled in PRIME Study Aimed at Accelerating Adoption of AI-Powered Portable MRI in Emergency Departments
Neutral
Business Wire
3 weeks ago
Hyperfine, Inc. to Announce Second Quarter 2025 Financial Results on August 13, 2025
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report financial results for the second quarter 2025 on Wednesday, August 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the reco.
Hyperfine, Inc. to Announce Second Quarter 2025 Financial Results on August 13, 2025
Neutral
Business Wire
4 weeks ago
Hyperfine Swoop® AI-Powered Portable MRI System Demonstrates 100% Sensitivity for ARIA-E Detection in New Data Presented at the 2025 Alzheimer's Association International Conference
TORONTO--(BUSINESS WIRE)--Swoop® AI-powered portable MRI system shows 100% sensitivity for ARIA-E detection in Lecanemab patients (CARE PMR study data presented at AAIC 2025).
Hyperfine Swoop® AI-Powered Portable MRI System Demonstrates 100% Sensitivity for ARIA-E Detection in New Data Presented at the 2025 Alzheimer's Association International Conference
Neutral
Business Wire
1 month ago
Hyperfine Swoop® AI-Powered Portable MRI System Showcased in Clinical Studies Designed to Broaden Access to Dementia Care
GUILFORD, Conn.--(BUSINESS WIRE)--New studies showcase the Swoop® MRI system's potential role in expanding access to dementia care and monitoring Alzheimer's treatment.
Hyperfine Swoop® AI-Powered Portable MRI System Showcased in Clinical Studies Designed to Broaden Access to Dementia Care
Charts implemented using Lightweight Charts™